8 completed. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow Finasteride: new trials by email Literature Review of Finasteride trials Research Report on Finasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) GV1001 placebo, Proscar placebo - Benign Prostatic Hyperplasia (BPH) | Phase 3 | Completed | GemVax & Kael | 423 | 2019-10-30 | 2022-08-25 |
| Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia P-3074, Finasteride, P-3074 Vehicle - Alopecia, Androgenetic | Phase 3 | Completed | Polichem S.A. | 458 | 2016-08-02 | 2019-06-20 |
| A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Tadalafil, Placebo, Finasteride - Benign Prostatic Hyperplasia, Enlarged Prostate | Phase 3 | Completed | Eli Lilly and Company | 696 | 2010-09-01 | 2013-02-27 |
| A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy Finasteride, Placebo - Enlarged Prostate | Phase 3 | Completed | University Health Network, Toronto | 19 | 2008-02-01 | 2015-12-09 |
| Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer. Flutamide, Finasteride, Placebo - Prostate Cancer, Prostatic Intraepithelial Neoplasia | Phase 2 / Phase 3 | Completed | Ente Ospedaliero Ospedali Galliera | 125 | 2004-01-01 | 2024-09-19 |
| A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140) MK0906, finasteride / Duration of Treatment: 48 weeks, Comparator: placebo / Duration of Treatment: 48 weeks - Benign Prostatic Hyperplasia | Phase 3 | Completed | Organon and Co | 600 | 2004-01-01 | 2024-08-15 |
| Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) MK0906, finasteride / Duration of Treatment : 48 Weeks, Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks - Androgenetic Alopecia | Phase 3 | Completed | Organon and Co | 355 | 1998-03-01 | 2022-02-17 |
| Medical Therapy of Prostatic Symptoms Doxazosin, Finasteride, Doxazosin placebo - Prostatic Hyperplasia, Prostatic Hypertrophy, Benign | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3407 | 1995-12-01 | 2018-09-28 |
Prostatic Hyperplasia (4) · Alopecia (2) · Prostatic Intraepithelial Neoplasia (1) · Prostatic Neoplasms (1)
Organon and Co (2) · Eli Lilly and Company (1) · Ente Ospedaliero Ospedali Galliera (1) · GemVax & Kael (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Polichem S.A. (1) · University Health Network, Toronto (1)
Belgium (2) · Canada (2) · Germany (2) · Italy (2) · Russia (2) · United States (2) · Argentina (1) · Brazil (1) · France (1) · Greece (1) · Hungary (1) · Mexico (1) · Poland (1) · South Korea (1) · Spain (1)
Andrea De Censi, MD (1) · Antonio Finelli, MD MSc FRCSC (1) · Claus Roehrborn (1) · E. David Crawford (1) · Eric Massana, MD (1) · Gary J. Miller (1) · Gerald L. Andriole (1) · Harris E. Foster (1) · Harry S. Clarke (1) · Herbert Lepor (1) · Joe W. Ramsdell (1) · John P. Foley (1) · Joseph A. Smith (1)
PMID 11796283, PMID 12689743, PMID 14681504, PMID 17196507, PMID 25353053, PMID 40683564
U01DK046472 (1)